Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Faron Pharmaceuticals Oy's 9-Day RSI or its related term are showing as below:
FRA:4FR's 9-Day RSI is ranked better than 58.02% of 1422
companies
in the Biotechnology industry
Industry Median: 47.095
vs FRA:4FR: 47.33
Faron Pharmaceuticals Oy (FRA:4FR) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Faron Pharmaceuticals Oy 9-Day RSI Related Terms
FRA:4FR vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Faron Pharmaceuticals Oy's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Faron Pharmaceuticals Oy 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Faron Pharmaceuticals Oy's 9-Day RSI falls into.
Faron Pharmaceuticals Oy (FRA:4FR) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Faron Pharmaceuticals Oy (FRA:4FR) has a 9-Day RSI of 47.33 as of Jul. 14, 2026. According to the industry distribution chart, Faron Pharmaceuticals Oy ranks #597 out of 1422 companies in the Biotechnology industry, placing it in the top 42%.
Is Faron Pharmaceuticals Oy's 9-Day RSI too high?
Faron Pharmaceuticals Oy's current 9-Day RSI is 47.33. The Biotechnology industry median 9-Day RSI is 47.10. Faron Pharmaceuticals Oy's value of 47.33 is 0.5% above this industry median. Based on the distribution chart, Faron Pharmaceuticals Oy ranks #597 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Faron Pharmaceuticals Oy ranks #597 out of 1422 companies for 9-Day RSI. This puts Faron Pharmaceuticals Oy in the upper half of its industry. The industry median 9-Day RSI is 47.10. Faron Pharmaceuticals Oy's value of 47.33 is 0.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 47.10, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Faron Pharmaceuticals Oy's current 9-Day RSI of 47.33 is 0.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 47.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Faron Pharmaceuticals Oy's current 9-Day RSI is 47.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current 9-Day RSI of 47.33. The current 9-Day RSI is 47.33 and 0.5% above the Biotechnology industry median of 47.10. Faron Pharmaceuticals Oy's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current 9-Day RSI is 47.33 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
29GF Score
Get the complete analysis for FRA:4FR
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4FR has been successfully added to your 
